{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:11:38Z","timestamp":1756897898144},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s10637-009-9283-z","type":"journal-article","created":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T05:19:53Z","timestamp":1245647993000},"page":"516-522","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"28","author":[{"given":"Byung Woog","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geundoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Sook","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Shin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,6,23]]},"reference":[{"key":"9283_CR1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","volume":"316","author":"T Philip","year":"1987","unstructured":"Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M (1987) High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med 316:1493\u20131498","journal-title":"N Engl J Med"},{"key":"9283_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235\u2013242","journal-title":"N Engl J Med"},{"key":"9283_CR3","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/S1083-8791(00)70028-0","volume":"6","author":"IW Flinn","year":"2000","unstructured":"Flinn IW, O\u2019Donnell PV, Goodrich A, Vogelsang G, Abrams R, Noga S, Marcellus D, Borowitz M, Jones R, Ambinder RF (2000) Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant 6:628\u2013632","journal-title":"Biol Blood Marrow Transplant"},{"key":"9283_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/sj.bmt.1703515","volume":"29","author":"T Flohr","year":"2002","unstructured":"Flohr T, Hess G, Kolbe K, Gamm H, Nolte H, Stanislawski T, Huber C, Derigs HG (2002) Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. Bone Marrow Transplant 29:769\u2013775","journal-title":"Bone Marrow Transplant"},{"key":"9283_CR5","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2005.08.012","volume":"23","author":"IF Khouri","year":"2005","unstructured":"Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin\u2019s lymphomas. J Clin Oncol 23:2240\u20132247","journal-title":"J Clin Oncol"},{"key":"9283_CR6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333:1540\u20131545","journal-title":"N Engl J Med"},{"key":"9283_CR7","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM (2001) Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 19:406\u2013413","journal-title":"J Clin Oncol"},{"key":"9283_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8:145\u2013154","journal-title":"Biol Blood Marrow Transplant"},{"key":"9283_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/bbmt.2002.v8.pm12374454","volume":"8","author":"A Kashyap","year":"2002","unstructured":"Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson BS (2002) Intravenous versus oral busulfan as part of a busulfan\/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8:493\u2013500","journal-title":"Biol Blood Marrow Transplant"},{"key":"9283_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/sj.bmt.1702433","volume":"25","author":"EA Copelan","year":"2000","unstructured":"Copelan EA, Penza SL, Pohlman B, Avalos BR, Goormastic M, Andresen SW, Kalaycio M, Bechtel TP, Scholl MD, Elder PJ, Ezzone SA, O\u2019Donnell LC, Tighe MB, Risley GL, Young DC, Bolwell BJ (2000) Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 25:1243\u20131248","journal-title":"Bone Marrow Transplant"},{"key":"9283_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s00277-001-0413-8","volume":"81","author":"M Hanel","year":"2002","unstructured":"Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F, Hanel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR (2002) Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 81:96\u2013102","journal-title":"Ann Hematol"},{"key":"9283_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/sj.bmt.1705841","volume":"40","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH (2007) Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu\/Cy\/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant 40:919\u2013924","journal-title":"Bone Marrow Transplant"},{"key":"9283_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","volume":"101","author":"BD Cheson","year":"2003","unstructured":"Cheson BD (2003) Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101:391\u2013398","journal-title":"Blood"},{"key":"9283_CR14","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1365-2141.2007.06869.x","volume":"139","author":"PF Ferrucci","year":"2007","unstructured":"Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, Ferrari M, Radice D, Papi S, Martinelli G, Paganelli G (2007) High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory\/resistant B-cell non-Hodgkin lymphomas. Br J Haematol 139:590\u2013599","journal-title":"Br J Haematol"},{"key":"9283_CR15","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","volume":"106","author":"A Nademanee","year":"2005","unstructured":"Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O\u2019Donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A (2005) A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106:2896\u20132902","journal-title":"Blood"},{"key":"9283_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.287.13.1640","volume":"287","author":"LM Crawford Jr","year":"2002","unstructured":"Crawford LM Jr (2002) From the food and drug administration. JAMA 287:1640","journal-title":"JAMA"},{"key":"9283_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","volume":"26","author":"A Krishnan","year":"2008","unstructured":"Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ (2008) Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:90\u201395","journal-title":"J Clin Oncol"},{"key":"9283_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.exphem.2007.01.043","volume":"35","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A (2007) Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin\u2019s lymphoma. Exp Hematol 35:534\u2013540","journal-title":"Exp Hematol"},{"key":"9283_CR19","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"9283_CR20","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:2453\u20132463","journal-title":"J Clin Oncol"},{"key":"9283_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2165\/00063030-200519050-00004","volume":"19","author":"BD Cheson","year":"2005","unstructured":"Cheson BD (2005) The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 19:309\u2013322","journal-title":"BioDrugs"},{"key":"9283_CR22","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.2174\/138945006778559157","volume":"7","author":"BD Cheson","year":"2006","unstructured":"Cheson BD (2006) Radioimmunotherapy of non-Hodgkin\u2019s lymphomas. Curr Drug Targets 7:1293\u20131300","journal-title":"Curr Drug Targets"},{"key":"9283_CR23","first-page":"114","volume":"91","author":"J Cilley","year":"2006","unstructured":"Cilley J, Winter JN (2006) Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica 91:114\u2013120","journal-title":"Haematologica"},{"key":"9283_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/10428190601158639","volume":"48","author":"JM Vose","year":"2007","unstructured":"Vose JM, Bierman PJ, Loberiza FR Jr, Bociek RG, Matso D, Armitage JO (2007) Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin\u2019s lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leuk Lymphoma 48:683\u2013690","journal-title":"Leuk Lymphoma"},{"key":"9283_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/sj.bmt.1705744","volume":"40","author":"HF Fernandez","year":"2007","unstructured":"Fernandez HF, Escalon MP, Pereira D, Lazarus HM (2007) Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 40:505\u2013513","journal-title":"Bone Marrow Transplant"},{"key":"9283_CR26","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","volume":"96","author":"OW Press","year":"2000","unstructured":"Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID (2000) A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934\u20132942","journal-title":"Blood"},{"key":"9283_CR27","first-page":"963","volume":"17","author":"M de Kreuk","year":"1996","unstructured":"de Kreuk M, Ossenkoppele GJ, Meijer CJ, Huijgens PC (1996) Prognostic factors for survival of non-Hodgkin\u2019s lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 17:963\u2013971","journal-title":"Bone Marrow Transplant"},{"key":"9283_CR28","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.1998.16.10.3264","volume":"16","author":"C Guglielmi","year":"1998","unstructured":"Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D, Cahn JY, Somers R, Sonneveld P, Gisselbrecht C, Van Der Lelie H, Chauvin F (1998) Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 16:3264\u20133269","journal-title":"J Clin Oncol"},{"key":"9283_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ijc.1018","volume":"96","author":"S Kunala","year":"2001","unstructured":"Kunala S, Macklis RM (2001) Ionizing radiation induces CD20 surface expression on human B cells. Int J Cancer 96:178\u2013181","journal-title":"Int J Cancer"},{"key":"9283_CR30","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ijrobp.2004.02.065","volume":"59","author":"MC Hernandez","year":"2004","unstructured":"Hernandez MC, Knox SJ (2004) Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin\u2019s lymphoma. Int J Radiat Oncol Biol Phys 59:1274\u20131287","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9283_CR31","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J Clin Oncol 20:3262\u20133269","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9283-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9283-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:38:46Z","timestamp":1678509526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9283-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,23]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["9283"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9283-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,23]]},"assertion":[{"value":"17 May 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}